Truist Securities Reiterates Buy on Coherus BioSciences, Maintains $22 Price Target
Portfolio Pulse from richadhand@benzinga.com
Truist Securities analyst Robyn Karnauskas has reiterated a 'Buy' rating on Coherus BioSciences (NASDAQ:CHRS) and maintained a price target of $22.
June 28, 2023 | 2:49 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Coherus BioSciences has received a reiterated 'Buy' rating from Truist Securities, with a maintained price target of $22.
The reiterated 'Buy' rating and maintained price target by Truist Securities indicates a positive outlook for Coherus BioSciences. This could potentially lead to an increase in investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100